Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Heron Therapeutics (HRTX) just unveiled an announcement.
Heron Therapeutics, Inc. recently announced that the FDA has received its application for the extended-release solution ZYNRELEF® and set a review completion goal date for September 23, 2024. This milestone could signify a significant development for the company and holds potential implications for investors tracking advances in pharmaceuticals and Heron’s market position.
Learn more about HRTX stock on TipRanks’ Stock Analysis page.
